Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

Vitrectomy for endogenous fungal endophthalmitis.

PURPOSE: The purpose of this study was to evaluate the predisposing risk factors and treatment outcomes of endogenous fungal endophthalmitis (EFE).

METHODS: Records of 25 patients (29 eyes), diagnosed with EFE and treated at Shanghai Eye, Ear, Nose & Throat Hospital from January 2002 to December 2006, were retrospectively reviewed. Four patients had bilateral disease. Final visual acuity and recurrence of EFE were evaluated.

RESULTS: Of these 25 patients diagnosed with EFE, 20 patients (22 eyes) were treated by pars plana vitrectomy. Of the remaining 5 patients (7 eyes), 3 cases (4 eyes) were cured by antifungal drugs through systemic treatment and intravitreal injection, but another 2 cases (3 eyes) were only given intravitreal injection because of severe general conditions. Of the 22 eyes that underwent pars plana vitrectomy, 16 (73%) eyes gained visual acuity of counting fingers or better. Recurrent EFE was happened in 2 eyes. Vitrectomy was repeated in 1 eye, another was subsequently enucleated due to phthisis. Vitreous culture-proven or smear-proven EFE occurred in 27 or 2 eyes, respectively. Candida albicans occurred in 17 of 29 eyes (59%), and other causative organisms were yeast fungus (3 eyes), Aspergillus niger (3 eyes), Actinomyces (2 eyes),Aspergillus flavus (1 eye), and Fusarium (1 eye).

CONCLUSION: Candida albicans were the most common causative organisms in EFE. The most common predisposing risk factors include recent major operation and intravenous administration in rural settings. Most patients with EFE will gain useful vision (counting fingers) after pars plana vitrectomy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app